血清VCAM-1及GLP-1水平与妊娠期糖尿病孕妇不良妊娠结局的相关性分析

目的探讨血管细胞黏附分子(vascular cell adhesion molecule-1,VCAM-1)及胰高血糖素样肽-1(glucagon like peptide-1,GLP-1)水平与妊娠期糖尿病孕妇不良妊娠结局的相关性。方法选择2016年1月至2019年1月在邢台市第三医院诊治的妊娠期糖尿病患者140例为观察组,同期产检正常孕妇140例为对照组。两组在入组后第2 d清晨空腹采集肘部静脉血,比较两组VCAM-1、GLP-1水平、妊娠结局及其相关性。结果观察组血清VCAM-1水平显著高于对照组,GLP-1水平显著低于对照组,差异有统计学意义(P<0.05);观察组的巨大儿、新生儿低血糖、剖宫产率显著高于对照组(P<0.05);对观察组进行多因素Logistic回归分析显示,VCAM-1水平升高(OR=3.106,P=0.017,95%CI:2.542-4.549),GLP-1水平降低(OR=2.674,P=0.024,95%CI:1.159-3.631)是不良母婴结局的危险因素。结论妊娠期糖尿病患者中血清VCAM-1、GLP-1水平发生较大变化,是不良妊娠结局的危险因素,在临床上可加强妊娠期糖尿病相关指标的监测,制定合理的治疗措施干预妊娠的结局。     

2型糖尿病合并高血压与血清某些元素的相关性分析

目的探讨2型糖尿病(Type 2 diabetes mellitus,T2DM)合并高血压发病与血清各元素水平的相关性,为控制T2DM病情提供更科学、更合理的依据。方法选取2015年3月至2016年5月乌鲁木齐市某三甲医院住院的1024例T2DM患者,将T2DM患者按照有无合并高血压分为T2DM合并高血压组和T2DM无合并高血压组,分析两组患者血清中的各元素水平及其与T2DM合并高血压发病之间的相关性。结果1024例T2DM患者中,627例合并高血压,占61.20%;397例患者无高血压,占38.80%;T2DM合并高血压组和T2DM无合并高血压组血清钠、镁水平之间差异有统计学意义(P<0.05);血清钠、镁水平与T2DM合并高血压正相关(P<0.05);血清钠水平的升高,血清镁水平的下降为T2DM合并高血压发病的相关因素。结论血清钠、镁水平与T2DM合并高血压发病呈正相关。血清钠水平的升高、镁水平的下降为T2DM合并高血压发病的相关因素。提示患者血清中各元素水平的差异在糖尿病病变的发生发展中具有一定的作用。     

运用《金匮要略》论治糖尿病便秘探析

糖尿病在中医里归于消渴范围内，“消渴”最初是在《黄帝内经》中被提起的，到了东汉张仲景的《金匮要略》对消渴进行更为详细记载。糖尿病便秘是糖尿病患者常见的并发症，张仲景对此也有独特见解。张仲景通过辨证论治，治病求本，谨遵病因病机，通过辨证分型，归纳出不同的有效方剂，为当代中医提供了极大的参考，应当进一步挖掘其学术思想，更好的服务于临床。     

补气养阴降糖饮联合二甲双胍治疗老年2型糖尿病的疗效观察

目的:观察补气养阴降糖饮加减联合二甲双胍治疗老年2型糖尿病(气阴两虚证)的效果。方法:选取2018年4月至2019年10月北京市和平里医院收治的老年2型糖尿病(气阴两虚证)患者84例作为研究对象,随机分为对照组和观察组,每组42例。2组均予以基础治疗,对照组予以二甲双胍口服,观察组予以补气养阴降糖饮加减联合二甲双胍治疗。比较2组治疗前后主症、次症及总评分、糖代谢水平、临床疗效、胰岛素抵抗指数水平及不良反应。结果:治疗后2组主症、次症及总评分,糖代谢水平、胰岛素抵抗指数水平均下降,且观察组较对照组降低的更为明显,差异均有统计学意义(P0.05);治疗后观察组总有效率高于对照组,差异有统计学意义(P0.05);观察组不良反应发生率与对照组比较,差异无统计学意义(P0.05),且不良反应均轻微。结论:对老年2型糖尿病气阴两虚证予以补气养阴降糖饮加减联合二甲双胍可有效控制症状,改善糖代谢,增强临床疗效,减轻胰岛素抵抗,且安全。     

Dimensions,application, and outcomes of person-centered self-management interventions for those living with type 2 diabetes: A scoping review

ObjectivesTo explore which dimensions of the person-centered approach (PCA) are adopted in self-management interventions, how they are applied, and its outcomes.MethodsA review team carried out a scoping review using the methodology of Arksey and O’Malley on diabetes mellitus type 2, person-centered care, and self-management.ResultsOf the 364 titles identified, 22 articles were included in this review. No study contained all five dimensions described by the person-centered framework. Some dimensions seemed difficult to assess, mainly having a sympathetic presence and engagement. The application of the five PCA dimensions are presented. Although the authors claimed their intervention to be person-centered, none used a specific tool to measure person-centered care in a holistic way.ConclusionAlthough the guidelines recommend a PCA to professionals, there is a gap with practice, professionals having difficulty adopting and measuring this approach.Practice implicationsSome strategies to facilitate the adoption of a PCA with people living with type 2 diabetes are proposed. These can help researchers and clinicians develop a PCA, by identifying the care delivery processes necessary to provide it. It seems important for researchers to measure whether their intervention is truly person-centered, using holistic tools and combining different methods (observation, questionnaire, interview).     

丹银海绵对糖尿病大鼠皮肤溃疡创面愈合的影响

目的:探讨丹银海绵对糖尿病大鼠皮肤溃疡创面愈合的影响。方法:将雄性Wistar大鼠随机分为8组。除空白对照组外,其余7组大鼠,通过手术在其背部形成一10mm×10mm相同大小,深达肌层的溃疡,分别给予抗生素、生长因子凝胶、纳米银、丹黄散,以及不同浓度的丹银海绵处理溃疡面。给药28d后处死大鼠,取溃疡部位新生肉芽组织,HE染色观察组织形态的变化;WesternBlot检测大鼠创面组织中AGEs、hs-CRP、IL-1、IL-6、bFGF、PDGF、VEGF表达水平。结果:病理切片观察显示适宜浓度的丹银海绵可以促进血管新生并伴扩张,同时生成大量新生成纤维细胞。WesternBlot检测显示高浓度的丹银海绵可以显著上调创面组织中生长因子表达(P<0.05),降低AGEs水平及炎症因子表达(P<0.05)。结论:适宜浓度的丹银海绵对于糖尿病大鼠皮肤溃疡的愈合有明显的促进作用,提高治疗效果。     

Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study

Abstract

Objective: To evaluate the long-term safety and effectiveness of biosimilar insulin glargine (GLY) in real-world clinical practice.

Methods: This prospective, non-interventional, multicenter, observational, post-marketing safety study (PMSS) enrolled Japanese patients with type 1 or 2 diabetes mellitus (T1DM or T2DM) starting GLY therapy, and was required by Japanese Pharmaceutical Affairs Law mandating post-marketing safety surveillance to acquire safety and effectiveness data of biosimilar products. Data collected from the 12-month observation included patient characteristics, adverse events, and blood glucose control.

Results: The study enrolled 141 patients with T1DM and 1104 patients with T2DM. Pre-study insulin was used by 94.1% of patients with T1DM and 75.0% with T2DM. 65.4% of patients with T1DM and 64.3% with T2DM switched from the reference product (GLY-switched), while 25.0% with T2DM were insulin-naive. Adverse events were reported by 5.7% and 8.5% in T1DM and T2DM, respectively. Similar incidences were reported in GLY-switched. Adverse events were reported by 10.7% in insulin-naive T2DM. Baseline mean hypoglycemic events/month were 1.8 and 0.1 in T1DM and T2DM, respectively: the mean change from baseline (CFB) was –1.2 (p?=?.066) and 0.0 (p?=?.915), respectively. Baseline mean HbA1c was 8.4% and 8.7% in T1DM and T2DM, respectively; the mean CFB was –0.5% (p?<?.001) and –0.9% (p?<?.001), respectively, and –1.5% (p?<?.001) in insulin-naive T2DM.

Conclusions: This first long-term Japanese PMSS of GLY demonstrated adverse events, hypoglycemia, and glycemic control consistent with the known GLY profile for T1DM and T2DM patients, in routine clinical practice.